Lipocine To Present At The Raymond James Human Health Innovation Conference

Rhea-AI Summary

Lipocine Inc. (NASDAQ: LPCN) announced its participation in the Raymond James Human Health Innovation Conference from June 21-23, 2021. The presentation is scheduled for June 21 at 12:40 PM ET. Interested parties can access the webcast here. The company focuses on metabolic and endocrine disorders, with key products including TLANDO, LPCN 1144, and others aimed at treating conditions such as hypogonadism and non-cirrhotic NASH.

SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference. The conference will be held virtually. Presentation details are below.

Raymond James Human Health Innovation Conference June 21-23

Presentation time:       June 21, 2021 starting at 12:40 PM ET         
Webcast link:              https://kvgo.com/rj-health/lipocine-inc-june-2021

The webcast of this presentation will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.  

About Lipocine Inc.
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study.  TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression.  For more information, please visit www.lipocine.com.   

View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-raymond-james-human-health-innovation-conference-301313327.html

SOURCE Lipocine Inc.

FAQ

When will Lipocine present at the Raymond James Human Health Innovation Conference?

Lipocine will present on June 21, 2021, at 12:40 PM ET.

How can I watch Lipocine's presentation at the Raymond James conference?

The presentation can be viewed through the webcast link: https://kvgo.com/rj-health/lipocine-inc-june-2021.

What is Lipocine's focus as a biopharmaceutical company?

Lipocine focuses on metabolic and endocrine disorders using proprietary drug delivery technologies.

What are some products in Lipocine's clinical development pipeline?

Lipocine's pipeline includes TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107.

What conditions does TLANDO address?

TLANDO is a treatment for conditions associated with a deficiency of endogenous testosterone, known as hypogonadism.

What clinical study has LPCN 1144 recently completed?

LPCN 1144 completed a proof-of-concept clinical study for non-cirrhotic NASH and is now in Phase 2 studies.